期刊文献+

Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway 被引量:6

暂未订购
导出
摘要 Although cisplatin is one of the chemotherapeutics most frequently used in oral squamous cell carcinoma(OSCC)treatment,it exerts multiple side effects and poor chemosensitivity.Nitrate reportedly demonstrates several beneficial biological functions,and synthesized nitrates enhance the therapeutic efficacy of chemotherapy.However,the role of inorganic nitrate in cisplatin chemotherapy remains unclear.We therefore investigated the effect of inorganic nitrate exerted on cisplatin sensitivity in OSCC.We found that nitrate did not affect OSCC cell growth and apoptosis in OSCC cells and OSCC xenograft tumor animal studies.Cisplatin induced REDD1 expression and AKT activation in OSCC.However,nitrate could increase cisplatin chemosensitivity,reduce its REDD1 expression,and attenuate AKT signaling activation in OSCC cells.Dysregulation of high levels of REDD1,which could enhance AKT activation,was positively associated with poor prognosis in OSCC patients.Thus,reduced REDD1 expression and retarded AKT activation induced by inorganic nitrate might be a new potential approach to the sensitization of oral cancer to cisplatin treatment in the future.
出处 《Science China(Life Sciences)》 SCIE CAS CSCD 2021年第11期1814-1828,共15页 中国科学(生命科学英文版)
基金 This work was supported by the CAMS Innovation Fund for Medical Sciences(2019-I2M-5-031) Beijing Hospitals Authority of Hospitals’Mission Plan(SML20151401,Capital Medical University) Beijing Municipality Government grants(Beijing Scholar Program—PXM2020_014226_000005,PXM2019_014226_000039,PXM2019_014226_000011,PXM2018_014226_000021,PXM2017_014226_000023,PXM2018_193312_000006_0028S643_FCG,PXM2016_014226_000034) the National Natural Science Foundation of China(91649124).
  • 相关文献

参考文献5

二级参考文献79

  • 1Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 2009,9:550 - 562.
  • 2Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth andmetabolism. Nat Rev Genet, 2006,7:606-619.
  • 3Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle, 2004,3:1221-1224.
  • 4Samuels Y, Wang Z, Bardelli A mutations of the PIK3CA gene , et al. High frequency of n human cancers. Science.2004,304:554.
  • 5Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002,2:489-501.
  • 6Bader AG, Kang S, Zhao L, et al. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer, 2005,5:921-929.
  • 7Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and elF4E in oncogenesis and cancer therapy. Nature, 2004,428:332-337.
  • 8Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell, 2000,103:253-262.
  • 9Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5" cap. Nature, 1990,345:544-547.
  • 10Dan HC, Sun M, Yang L, et al. Phosphatidylinositol 3-kinase/ Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem, 2002,277: 35364-35370.

共引文献91

同被引文献15

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部